BTIG Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $14

Benzinga Newsdesk www.benzinga.com Neutral 62.1%

Neg 0% Neu 62.1% Pos 0%

BTIG analyst Jeet Mukherjee initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $14.